UNI-BIO GROUP released its interim results, with a net profit of HKD 75.955 million, a year-on-year increase of 12.7%
UNI-BIO GROUP released its mid-term results for 2025, with revenue of HKD 310 million, a year-on-year increase of 13.4%; net profit of HKD 75.955 million, a year-on-year increase of 12.7%; and basic earnings per share of HKD 1.27. The growth in performance is attributed to the expansion of sales channels, increased demand for BoguTai®, and market attention to already listed drugs, reflecting the group's strategic effectiveness in operational efficiency, cost control, and commercial execution
According to the Zhitong Finance APP, UNI-BIO GROUP (00690) released its interim results for 2025, with revenue of HKD 310 million, a year-on-year increase of 13.4%; net profit of HKD 75.955 million, a year-on-year increase of 12.7%; and basic earnings per share of HKD 1.27.
The increase in profit during the period is mainly attributed to the expansion of the group's sales channels, the growing demand for Bogu Tai®, and the continued market attention on the group's listed drugs. This also reflects the strategic effectiveness of the group's focus on operational efficiency, strict cost control, and precise business execution, further consolidating its trajectory of sustained profit growth and long-term value creation
